Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

Imaging tech promises deepest looks yet into living brain tissue at single-cell resolution

Both for research and medical purposes, researchers have spent decades pushing the limits of microscopy to produce ever deeper and sharper images of brain activity, not only in the cortex but also in regions underneath such as the hippocampus. In a new study, a team of MIT scientists and engineers demonstrates a new microscope system capable of peering exceptionally deep into brain tissues to detect the molecular activity of individual cells by using sound.

“The major advance here is to enable us to image deeper at single-cell resolution,” said neuroscientist Mriganka Sur, a corresponding author along with mechanical engineering Professor Peter So and principal research scientist Brian Anthony. Sur is the Paul and Lilah Newton Professor in The Picower Institute for Learning and Memory and the Department of Brain and Cognitive Sciences at MIT.

In the journal Light: Science and Applications, the team demonstrates that they could detect NAD℗H, a molecule tightly associated with cell metabolism in general, and electrical activity in neurons in particular, all the way through samples such as a 1.1 mm “cerebral organoid,” a 3D-mini -like tissue generated from human stem cells, and a 0.7 mm thick slice of mouse brain tissue.

Researchers uncover dozens of traits driven by maternal versus paternal genes

Researchers developed a high-accuracy method to infer whether genetic variants come from the mother or father without needing parental genomes, analysing 286,666 UK Biobank participants. They uncovered over 30 parent-of-origin effects on traits from growth and metabolism to diabetes, many showing opposite effects depending on parental source.

Stem Cell Therapy Offers Hope for Repairing Brain Damage in Newborns

Oxygen deprivation around birth can lead to brain damage in babies, with far-reaching consequences. A new stem cell treatment administered via nasal drops is showing promising results. In a safety study conducted at UMC Utrecht, called PASSIoN, ten newborns received this ‘intranasal stem cell therapy’ shortly after birth. Most of the children showed remarkably positive development: they started walking earlier on average than untreated children with comparable brain damage, had no motor impairments, and none developed epilepsy or visual problems. The study results were published today in the scientific journal Stroke.

All ten babies in the study had a perinatal stroke: a type of brain injury that occurs just before, during, or shortly after birth, damaging the developing brain. This kind of injury can lead to long-term neurological problems such as cerebral palsy (CP), a condition that affects movement due to early brain damage.

Replacing brain immune cells in mice slows neurodegeneration in Stanford Medicine study

By Krista Conger

The technique, which used genetically healthy donor cells, prolonged life and function in mice with a disease similar to Tay-Sachs. It may help with other neurodegenerative diseases like Alzheimer’s.

Liz Parrish: Why She Risked Everything on an Unproven Treatment

What would you do if medicine offered no answers?

Liz Parrish didn’t wait for FDA approval. She became the first person in the world to take multiple gene therapies, using her own body to test a future that medicine wasn’t ready for.

Since then, she’s taken 10 gene therapies, helped over 300 people treat conditions once considered untreatable, and challenged one of the biggest assumptions in healthcare:

👉 Should we treat aging the same way we treat disease?

In this talk, Liz shares how her personal decision created ripple effects across the world — and why gene therapy may be the first real step toward extending not just health span, but lifespan.

What you’ll hear:

Continue reading “Liz Parrish: Why She Risked Everything on an Unproven Treatment” | >

CRISPR-GPT Turns Novice Scientists into Gene Editing Experts

CRISPR technology has revolutionized biology, largely because of its simplicity compared to previous gene editing techniques. However, it still takes weeks to learn, design, perform, and analyze CRISPR experiments; first-time CRISPR users often end up with low editing efficiencies and even experts can make costly mistakes.

In a new study, researchers from Stanford University, Princeton University, and the University of California, Berkeley, teamed up with Google DeepMind to create CRISPR-GPT, an artificial intelligence (AI) tool that can guide researchers through every aspect of CRISPR editing from start to finish in as little as one day.1 The results, published in Nature Biomedical Engineering, demonstrate that researchers with no previous CRISPR experience could achieve up to 90 percent efficiency in their first shot at gene editing using the tool.

CRISPR-GPT is a large language model (LLM), a type of AI model that uses text-based input data. Led by Le Cong of Stanford University and Mengdi Wang of Princeton University, the team trained the model on over a decade of expert discussions, as well as established protocols and peer-reviewed literature. They designed it to cover gene knockout, base editing, prime editing, and epigenetic editing systems, and benchmarked the tool against almost 300 test questions and answers.

First gene-edited islet transplant in a human passes functional trial

Uppsala University Hospital-led investigators report that gene-edited donor islet cells survived 12 weeks inside a man with long-standing type 1 diabetes without any immunosuppressive medication.

Intensive insulin therapy can delay complications and improve life expectancy. Early-onset type 1 diabetes remains linked to reduced quality of life, serious cardiovascular risk, and shortened lifespan. Toxicity from lifelong immune suppression also drives morbidity and mortality in organ recipients.

In the study, “Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression,” published in the New England Journal of Medicine, researchers conducted a first-in-human open-label trial to test whether hypoimmune-engineered islet cells could evade rejection.

Johns Hopkins scientists grow novel ‘whole-brain’ organoid

Johns Hopkins University researchers have grown a novel whole-brain organoid, complete with neural tissues and rudimentary blood vessels—an advance that could usher in a new era of research into neuropsychiatric disorders such as autism.

“We’ve made the next generation of brain organoids,” said lead author Annie Kathuria, an assistant professor in JHU’s Department of Biomedical Engineering who studies brain development and neuropsychiatric disorders. “Most brain organoids that you see in papers are one brain region, like the cortex or the hindbrain or midbrain. We’ve grown a rudimentary whole-brain organoid; we call it the multi-region brain organoid (MRBO).”

Chinese Scientists Unveil Major Breakthrough in Large-scale DNA Editing

Chinese scientists have developed a gene editing technology capable of precisely manipulating large DNA segments ranging from thousands to millions of base pairs in both plant and animal cells, marking a significant advance in the field of life sciences.

The research team from the Institute of Genetics and Developmental Biology at the Chinese Academy of Sciences announced the new technology in a study published online Monday in the journal Cell.

The method, called PCE (Programmable Chromosomal Engineering), combines three innovative techniques to enable programmable editing of large chromosome segments. In lab tests, researchers successfully inserted an 18,800-base-pair DNA fragment, replaced a 5,000-base-pair sequence, inverted a 12-million-base-pair chromosomal region, deleted a 4-million-base-pair segment, and even relocated entire chromosomes.

/* */